Authors
Shan Yuan, Dongyun Yang, Ryotaro Nakamura, Monzr M Al Malki, Amandeep Salhotra, Michelle Afkhami, Shirong Wang
Published in
Vox sanguinis. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
The hematopoietic cell transplantation comorbidity index (HCT-CI) is widely used to evaluate non-relapse mortality (NRM) risks after HCT. We aimed to evaluate whether the lack of transfusion independence (TI) by Day 30 predicted increased NRM independently of HCT-CI in acute myeloid leukemia (AML) allogeneic (allo-) HCT recipients.
The relationships between HCT-CI, TI, and NRM were evaluated using multivariate analyses in this single-center retrospective study.
A total of 676 AML allo-HCT recipients were evaluated, including 234 (35%) with HCT-CI score ≥3. Median follow-up among survivors (n = 307) was 7.1 years (range: 2.7-11.8). High (≥3) HCT-CI score was significantly associated with increased NRM at 2 years but showed no correlation with attainment of red blood cell (RBC) or platelet (PLT) TI by Day 30. However, the lack of RBC or PLT TI by Day 30 predicted higher NRM independently of HCT-CI. The 2-year NRM incidences were 0.297 (95% confidence interval [CI]: 0.246-0.350) versus 0.137 (95% CI: 0.105-0.174) for those without or with RBC TI, with adjusted hazard ratio (aHR) of 2.02 (95% CI: 1.44-2.84, p < 0.001). For those without and with PLT TI, the NRM incidences were 0.374 (95% CI: 0.276-0.471) and 0.179 (95% CI: 0.149-0.212), with aHR of 2.07 (95% CI: 1.30-3.29, p = 0.002). Patients with both high HCT-CI scores and lack of TI by Day 30 had the highest NRM incidence.
Lack of TI by Day 30 is an early post-HCT warning sign which predicted increased 2-year NRM independently of HCT-CI and can be combined with HCT-CI to further stratify NRM risks.
PMID:
43039460
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0